SBP-101 is under clinical development by Spark Biopharma and currently in Phase I for Glioblastoma Multiforme (GBM). According to GlobalData, Phase I drugs for Glioblastoma Multiforme (GBM) have an 82% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how SBP-101’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
SBP-101 overview
SBP-101 (SB17170) is under development for the treatment of solid tumor, biliary tract cancer, hepatocellular carcinoma, glioblastoma multiforme (GBM), idiopathic pulmonary fibrosis (IPF), melanoma and cholangiocarcinoma. It acts by targeting high mobility group protein B1 (HMGB1). It is administered by oral route. The drug candidate is developed based on privileged-substructure based diversity-oriented synthesis (p-DOS) technology. It is a prodrug of SB1703.
Spark Biopharma overview
Spark Biopharma is a bio pharmaceutical manufacturing company that involves in manufacture of small molecule therapeutics through the integration of chemistry, biology, informatics and proteomics. The company’s therapeutic drug is produced by the compound library and bio probe developed with domestic original technology. It technologies involves in molecular diversity using pDOS strategy, phenotype-based drug discovery with novel screening platform using fluorescent bioprobes. The company is headquartered in Gwanak-g, South Korea.
For a complete picture of SBP-101’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
